Pages that link to "Q36037466"
Jump to navigation
Jump to search
The following pages link to Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. (Q36037466):
Displaying 50 items.
- Peer support for schizophrenia (Q24202186) (← links)
- Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis (Q24606868) (← links)
- Cancer care for individuals with schizophrenia (Q27009111) (← links)
- Clozapine-induced mitochondria alterations and inflammation in brain and insulin-responsive cells (Q28488537) (← links)
- Characterization of schizophrenia adverse drug interactions through a network approach and drug classification (Q28679280) (← links)
- European network for promoting the physical health of residents in psychiatric and social care facilities (HELPS): background, aims and methods (Q33498111) (← links)
- Differences in mortality and suicidal behaviour between treated and never-treated people with schizophrenia in rural China (Q33572071) (← links)
- The use of psychiatric drugs and worsening body mass index among inpatients with schizophrenia (Q33718231) (← links)
- Mortality in schizophrenia: clinical and serological predictors (Q33762540) (← links)
- Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia (Q33768017) (← links)
- Are women with psychosis receiving adequate cervical cancer screening? (Q33815330) (← links)
- Initial medical work‐up of first‐episode psychosis: a conceptual review (Q33829975) (← links)
- Prevalence of night eating in obese individuals with schizophrenia and schizoaffective disorder (Q33870502) (← links)
- Schizophrenia and the alpha7 nicotinic acetylcholine receptor (Q34002872) (← links)
- Incident somatic comorbidity after psychosis: results from a retrospective cohort study based on Flemish general practice data (Q34086096) (← links)
- Review: Are there modifiable risk factors which will reduce the excess mortality in schizophrenia? (Q34183495) (← links)
- Coronavirus immunoreactivity in individuals with a recent onset of psychotic symptoms (Q34415902) (← links)
- Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia (Q34486175) (← links)
- Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia (Q34631349) (← links)
- Insomnia is frequent in schizophrenia and associated with night eating and obesity (Q34631745) (← links)
- The effectiveness of lifestyle interventions to reduce cardiovascular risk in patients with severe mental disorders: meta-analysis of intervention studies. (Q34760060) (← links)
- A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia (Q34974099) (← links)
- Preliminary Examination of Olanzapine and Diet Interactions On Metabolism in a Female Macaque (Q34993531) (← links)
- Cigarette smoking and mortality risk in people with schizophrenia (Q35065406) (← links)
- Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia (Q35082389) (← links)
- Mortality among long-stay patients with schizophrenia during the setting-up of community facilities under the Yuli model (Q35136374) (← links)
- Poor clinical outcomes among pneumonia patients with schizophrenia (Q35177084) (← links)
- Pharmacogenetics of antipsychotic-induced side effects (Q35237129) (← links)
- Premature death in adults with 22q11.2 deletion syndrome (Q35281099) (← links)
- Efficacy of lifestyle interventions in physical health management of patients with severe mental illness (Q35290463) (← links)
- Accuracy of self-reported medical problems in patients with alcohol dependence and co-occurring schizophrenia or schizoaffective disorder (Q35376156) (← links)
- A weighted and integrated drug-target interactome: drug repurposing for schizophrenia as a use case (Q35671408) (← links)
- Treatment of tobacco use disorders in smokers with serious mental illness: toward clinical best practices (Q35701489) (← links)
- Making the journey with me: a qualitative study of experiences of a bespoke mental health smoking cessation intervention for service users with serious mental illness (Q36045863) (← links)
- Illicit drug use in heavy smokers with and without schizophrenia (Q36087073) (← links)
- Lost in the Rush to National Reform: Recommendations to Improve Impact on Behavioral Health Providers in Rural Areas (Q36151910) (← links)
- High Prevalence of Obesity, Hypertension, Hyperlipidemia, and Diabetes Mellitus in Japanese Outpatients with Schizophrenia: A Nationwide Survey (Q36195246) (← links)
- Anthropometric parameters as indicators of metabolic derangements in schizophrenia patients stabilized on olanzapine in an Indian rural population (Q36420353) (← links)
- Adherence to common cardiovascular medications in patients with schizophrenia vs. patients without psychiatric illness (Q36421831) (← links)
- Inequalities in lung cancer care of elderly patients with schizophrenia: an observational cohort study (Q36561220) (← links)
- The catatonic dilemma expanded (Q36588430) (← links)
- A Review of Brain-derived Neurotrophic Factor as a Candidate Biomarker in Schizophrenia (Q36600804) (← links)
- Mortality among patients with schizophrenia and vocational rehabilitation program services under Taiwan's psychiatric care reform (Q36790443) (← links)
- Toxoplasma gondii in individuals with schizophrenia: association with clinical and demographic factors and with mortality (Q36853303) (← links)
- An Open Trial of Relapse Prevention Therapy for Smokers With Schizophrenia (Q36898885) (← links)
- Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia. (Q36909124) (← links)
- Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder (Q36934711) (← links)
- Smoking status as a potential confound in the BOLD response of patients with schizophrenia. (Q36959123) (← links)
- Medical comorbidity in patients with schizophrenia and alcohol dependence (Q37114044) (← links)
- The impact of obesity on health care costs among persons with schizophrenia (Q37139663) (← links)